Urology Times staff

“I think this is a nice cluster of podcasts that really go at this from different angles,” says Stacy Loeb, MD, MSc.

"I think that it's important to have a clear understanding and articulation of what the shared goals are," says Mark S. Litwin, MD, MPH.

“Although people will look back and say, how in the world do urology and gastroenterology fit in with each other? They have everything to do with each other because we focus on the foundation,” says Michelle Pearlman, MD.

The phase 2 SALV-ENZA trial explored whether the addition of enzalutamide to salvage radiation therapy could improve outcomes in patients with high-risk, PSA-recurrent prostate cancer after radical prostatectomy.

“Effective January 1, 2023, anyone who performs a laparoscopic simple prostatectomy should be using CPT code 55867 to report that procedure,” says Jonathan Rubenstein, MD.

Combining the approved antibody-drug conjugates with other agents in this space may provide some synergy and allow even more efficacy and disease control, explains Alicia Morgans, MD.

Benjamin Lowentritt, MD, discusses how the phase 3 SPOTLIGHT trial showed the efficacy of the PSMA-PET imaging agent 18F-rhPSMA-7.3 PET across a variety of subgroups in prostate cancer.

“What's more concerning is we're seeing an increase in advanced or late-stage diagnosis, which I've seen in my practice as well,” says Derek J. Lomas, MD, PharmD.

"What came out of that meeting was looking at wellness and burnout as a preventative thing," says Diana Londoño, MD.

In this interview, Ira Sharlip, MD, explains the potential dangers these products pose and what urologists can do to help protect their patients.

“We need to do better, and men in America deserve a better chance at long-term, good outcomes from their prostate cancer discovery,” says Michael S. Cookson, MD, MMHC.

"I think that to be a successful mentee, you have to view the relationship with your mentor as a 2-way street," says Mark S. Litwin, MD, MPH.

“So many patients with prostate cancer qualify for genetic testing, but it's currently underutilized,” says Stacy Loeb, MD, MSc.

"The other things that are important are to use the privilege that you have as a senior mentor, even as a mid-level or junior mentor, to help open doors for people and make connections," says Mark S. Litwin, MD, MPH.

“This study is one of the most highly anticipated of all of the metastatic hormone-sensitive setting trials that we have going on at this time,” says Alicia Morgans, MD, MPH.

"Patients with intermediate-risk NMIBC remain an incredibly heterogeneous group," says Wei Shen Tan, MD, PhD.

“The benefits can be reaped by the vast majority of patients and because we're really undertreating these patients, we need to make a conscious effort to overcome whatever barriers are facing us,” says Alicia Morgans, MD, MPH.

"The first takeaway I would say is that there is not only a lot of passion for each of these different areas in our society, but also there's a lot of expertise and experience within our urologic community from which we can all draw upon," says Manoj Monga, MD, FACS.

“These are codes that had not been updated in decades—since they were originally written,” says Jonathan Rubenstein, MD.

“I think really identifying who's going to benefit from what combination for how long is going to be important,” says Stephanie Berg, DO.

Several treatments are being explored across these trials, including pembrolizumab, nivolumab, enfortumab vedotin, durvalumab, avelumab, and cabozantinib.

“Now, we only have 1 code set that we have to worry about instead of 2 code sets,” says Jonathan Rubenstein, MD.

“We don’t want to subject patients to a therapeutic strategy that they are unlikely to benefit from,” says Atish D. Choudhury, MD, PhD.

“Practices need to be aware that they need to be able to budget for those who perform in-office services that have very little clinical labor, but may have a high practice expense overall,” Jonathan Rubenstein, MD, says.

“Every year, we see our reimbursements go down. Every year, there seem to be some sort of patch,” says Jonathan Rubenstein, MD.

“There are a slew of ongoing trials looking at 177Lu-PSMA-617 in earlier stages of disease,” says Praful Ravi, MB, BChir, MRCP.

“We have to remember that this is not a cure for prostate cancer…right now, it is another tool in the toolbox,” says Praful Ravi, MB, BChir, MRCP.

“We found many factors in urology that were associated with the inability to follow through with a video visit,” says Kevin Shee, MD, PhD.

In this interview, Arvin K. George, MD, gives an overview of the current state of focal therapy and also discusses 2 clinical trials evaluating new technologies in the space.

Slovin says what’s interesting about the CAR-T platform she’s been exploring is that “we see pretty exquisite sensitivity to the cancer cells.”